参考文献/References:
[1] Xu Y,Wang L,He J,et al. Prevalence and control of diabetes in Chinese adults[J].JAMA,2013,310(9):948-959.DOI:10.1001/jama.2013.168118.
[2] Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic fatty liver:a possible new target for type 2 diabetes prevention and treatment[J].Int J Mol Sci,2013,14(11):22933-22966.DOI:10.3390/ijms141122933.
[3] Armstrong MJ,Houlihan DD,Rowe IA,et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program[J].Aliment Pharmacol Ther,2013,37(2):234-242.DOI:10.1111/apt.12149.
[4] Wang XC,Gusdon AM,Liu H,et al.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation[J].World J Gastroenterol,2014,20(40):14821-14830.DOI:10.3748/wjg.v20.i40.14821.
[5] Wang YG, Yang TL. Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway[J].Exp Ther Med,2015,10(5):1777-1783. DOI:10.3892/etm.2015.2741.
[6] Gupta NA,Mells J,Dunham RM,et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway[J].Hepatology,2010,51(5):1584-1592.DOI:10.1002/hep.23569.
[7] 赵昕怡,张利莉,索朗曲珍,等. 利拉鲁肽改善非酒精性脂肪性肝病小鼠肝脂肪沉积的机制探讨[J]. 中华肝脏病杂志,2014,22(11):849-853. DOI:10.3760/cma.j.issn.1007-3418.2014.11.010.
[8] He Q,Sha S,Sun L,et al.GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway[J].Biochem Biophys Res Commun,2016,476(4):196-203.DOI:10.1016/j.bbrc.2016.05.086.
[9] Chalkiadaki A,Guarente L.Sirtuins mediate mammalian metabolic responses to nutrient availability[J].Nat Rev Endocrinol,2012,8(5):287-296.DOI:10.1038/nrendo.2011.225.
[10] Li Y,Xu S,Giles A,et al.Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver[J].FASEB J,2011,25(5):1664-1679.DOI:10.1096/fj.10-173492.
[11] Li Y,Wong K,Giles A, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21[J].Gastroenterology,2014,146(2):539-549.e7.DOI:10.1053/j.gastro.2013.10.059.
[12] Xu F, Li Z, Zheng X,et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis[J].Diabetes,2014,63(11):3637-3646.DOI:10.2337/db14-0263.
[13] Tong W,Ju L,Qiu M,et al. Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3 a pathway[J].Hepatol Res,2016,46(9):933-943.DOI:10.1111/hepr.12634.
[14] Liu Y,Wei R,Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease[J].World J Gastroenterol,2014,20(27):9090-9097.DOI:10.3748/wjg.v20.i27.9090.
[15] Gupta NA, Mells J, Dunham RM,et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway[J].Hepatology,2010,51(5):1584-1592.DOI:10.1002/hep.23569.
[16] 侯洪涛,裘艳梅,张建,等. GLP-1下调非酒精性脂肪肝大鼠SOCS-3和SREBP-1c的表达[J]. 中国病理生理杂志,2016,32(7):1312-1316.DOI:10.3969/j.issn.1000-4718.2016.07.026.
[17] 徐嘉妤,敖娜,都健,等.胰升糖素样肽1类似物对非酒精性脂肪肝大鼠IREl0L-JNK通路的干预效应[J]. 中华内分泌代谢杂志,2015,31(3):272-276.DOI:10.3760/cma.j.issn.1000-6699.2015.03.018.
[18] Zhang L,Yang M,Ren H,et al. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK[J].Liver Int,2013,33(5):794-804.DOI:10.1111/liv.12120.
[19] 李春君,于德民. GLP-1受体激动剂治疗非酒精性脂肪肝的新进展[J].天津医药,2015,(11):1230-1234.DOI:10.1172/JCI44271.
[20] Decara J,Arrabal S,Beiroa D,et al. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators[J].Biofactors,2016,42(6):600-611.DOI:10.1002/biof.1295.
[21] Zhou M,Mok MT,Sun H,et al.The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis[J].Oncogene, 2017,36(29):4135-4149.DOI:10.1038/onc.2017.38.
[22] 高慧亭,徐丽姝,李东风,等. GLP-1对非酒精性脂肪肝大鼠肝氧化应激及TNF-α、TGF-β1的影响[J]. 南方医科大学学报,2013,33(11):1661-1664.
[23] 周小俐. GLP-1对非酒精性脂肪肝病大鼠的作用及对PKCε、TLR4/NF-κB信号通路的影响[D]. 广州:南方医科大学,2015.
[24] Oh YS, Lee YJ, Kang Y, et al. Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors[J].J Endocrinol,2013,216(3):343-352.DOI:10.1530/JOE-12-0311.
相似文献/References:
[1]曹涵,曲伸.过氧化物酶体增殖物活化受体与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
Cao Han,Qu Shen..Peroxisome proliferator-activated receptors and non-alcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2014,(03):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
[2]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(03):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[3]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(03):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[4]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(03):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[5]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(03):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[6]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(03):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[7]聂秀玲,李明珍,孙丽荣.高尿酸血症与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(03):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[8]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(03):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[9]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(03):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[10]张洁,邸阜生.运动防治非酒精性脂肪性肝病的机制[J].国际内分泌代谢杂志,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
Zhang Jie,Di Fusheng..Mechanism of exercise on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2016,36(03):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]